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Interferon Retinopathy in a Monoinfected Hepatitis C Patient 
A Case Report 
 





Retinopathy associated with alpha-interferon therapy is a common finding for patients 
with progressive Hepatitis C.  My report is on a case presentation of interferon 
retinopathy and transient visual disturbance in a patient being treated for progressive 
Hepatitis C.  
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Introduction:  
Patients on anti-viral therapy for Hepatitis C are at risk of developing retinopathy. The 
exact pathogenesis of interferon retinopathy is unknown at this time, but the retinal 
presentation is very similar to immunocompromised and systemic vascular disease 
manifestations.  I present a case of interferon retinopathy in an immunocompetent patient 
with chronic Hepatitis C and discuss current advances in treatment for Hepatitis C.  
 
Case Report: 
A 45-year old Caucasian male presented with the chief concern of a new “blurry spot” in 
the right temporal visual field.  He also reported a slow decrease in his visual clarity over 
the last “couple of months.” He attributed the visual symptoms to the new medication he 
had been taking for Hepatitis C (HCV).  The patient denied any previous episodes of 
vision loss or blurred vision. This was his first eye exam. 
Best corrected visual acuities were 20/20 right eye (OD) and 20/20 in the left eye (OS).  
Extraocular muscle testing showed no restrictions. Pupils were equal, round, and reactive 
to light with no relative afferent pupillary defect.  Biomicroscopy revealed only mild 
pingueculae OU for which the patient was asymptomatic. 
A frequency doubling technique (FDT) visual field screening N-30-5 showed no defects, 
but questionable reliability of the test in the left eye. The right eye had no defects and was 
reliable.  
A dilated fundus exam revealed five large cotton wool spots in the posterior pole of the 
right eye and six cotton wool spots in the posterior pole of the left eye.  No hemorrhages, 
microaneurysms, or retinal edema were detected. The blood vessels were of healthy 
caliber and no artery-vein crossing changes were noted. The cup- to- disc ratio of the 
optic nerves was 0.40 round in each eye, and the margins of the discs were distinct. One 
of the cotton wool spots OD correlated to the subjective location of temporal blur for the 
patient. The initial retinal findings can be seen in Figure 1. 
A review of the patient’s medical history and medical records confirmed he was 
prescribed a daily interferon (Alphacon) injection regimen of 0.5mL/15mcg daily to treat 
liver cirrhosis caused by HCV.  The patient was also taking Ribivarin 200mg caplets 
three times daily to supplement the interferon therapy.  The combination interferon 
therapy was initiated three months prior to the initial eye examination.  The patient had 
no other medical conditions diagnosed by his primary care physician or liver specialists 
and was not taking any other medications.  He reported, and medical records confirmed 
he was negative for hypertension, diabetes mellitus and the Human Immunodeficiency 
Virus (HIV).  The patient had also quit smoking within the last year and stopped alcohol 
use two years prior. 
The diagnosis of Interferon Retinopathy in both eyes (OU) was made based on the 
systemic health findings and isolated cotton wools spots.  The possibility of a branch 
retinal occlusion was not yet ruled out OD in correlation with the perceived visual 
disturbance.  The patient was scheduled to return to a retinal specialty clinic within one 
month for a fluorescein angiography (FA) and retinal evaluation.  The patient’s liver 
specialists and primary care doctors were also made aware of the findings. 
 
Retinal Follow-Up #1: 
Two weeks later the patient reported that he could “barely notice” the intermittent blurry 
spot in his temporal visual field OD that he had mentioned at the first visit.  His fourth 
month of the interferon therapy continued. 
Visual acuity was stable OU. Another FDT Visual Field Screener N-30-5 showed 
identical results to the first visit: no defects, but questionable reliability OS, with 2/3 
fixation errors. Once again, the subjective superior- temporal defect noted at the last visit 
was not identified with the screening field. 
The dilated fundus exam revealed an increase in the amount of cotton wool spots: OD 
had nine large and four small cotton wool spots and OS had twelve large cotton wool 
spots in posterior pole. There was no technician available to perform the FA or photos at 
this appointment, so an imaging appointment was set for the following week. The 
patient’s liver care team was notified of the findings again. 
 
Retinal Follow-Up #2 
The patient returned for a FA and color photos, as scheduled (Figure 2). His unaided 
visual acuity remained stable. The FA showed “no obvious involvement of the vessels or 
microvasulature immediate to the fovea.”  There were some microvascular changes seen 
in the arcades supero-temporally OD and infero-temporally OS. The cotton wool spots 
did block and stain “a little” (Please note that while FA was reported as being done, the 
angiography photos were not provided by the retinal specialist). 
The patient was educated that the changes in his eye were likely to be from his interferon 
therapy and that there might be a possibility of macular involvement in the future. The 
patient still elected to continue his HCV therapy.  It was decided that close retinal 
monitoring would occur. 
 
Retinal Follow-Up # 3 
One month later, per FA, no ischemia was noted at the foveal region (Figure 3).  The 
cotton wool spots were relatively stable, with the disappearance of some and the 
appearance of new cotton wools spots to take their place in other locations through the 
posterior pole (Figure 3-5). The patient still elected to continue with HCV interferon 
therapy. He was scheduled for retinal monitoring in 12 weeks.  
 
Liver Specialty Clinic Follow-Up Summary: 
Six months after the appearance of the interferon retinopathy, the patient’s viral load 
testing did not show any change from the time he had initiated interferon therapy: the 
viral load was low, but detectable.  The HCV antiviral therapy was tapered at this point, 
as his liver team stated that “research confirmed that there would not be a sustained viral 
response unless the virus is undetectable during treatment, and that prolonged treatment 
does not help past this time.” He was instructed to take a 50% dose three times and 
dispose of the rest of the interferon.   
 
Retinal Follow-Up #4 
A dilated eye-exam occurred two months after the cessation of his interferon treatment. It 
appeared that the concentration and size of the cotton wools spots had decreased. A 
follow-up appointment was made for six months to monitor resolution of the interferon 
retinopathy. His ocular prognosis was determined to be excellent.  The patient was lost-to 
follow-up, so it is unknown if he has sought treatment for his liver disease with the newer 
HCV treatments FDA approved end of 2013 and 2014. 
 
Figure 1: Cotton Wool Spots detected at Initial Exam 
 
 Figure 2: Interferon Retinopathy OU at Month 2 
 
 
Figure 3: Fluorescein Angiography Showing Cotton Wool Spots in Interferon 
Retinopathy  
Early Phase (left), Late Phase (right) 
 
 









Alpha interferon is a drug used to treat multiple viral and malignant systemic conditions, 
most commonly Hepatitis C (2,3,4,5).  Different types of cancer (7,9) and multiple sclerosis 
(3) are also less commonly treated with interferon.    
Hepatitis C is a blood-borne RNA (ribonucleic acid) virus that specifically targets the 
liver and can lead to severe chronic liver (cirrhosis and fibrosis) disease over time (5). 
Cirrhosis was the 8th leading cause of death in the United States in 2010 (12).  In advanced 
stages, the liver damage is irreversible and can necessitate a liver transplant. The National 
Institute of Diabetes and Digestive and Kidney Disease (NIDDK) of the National 
Institute of Health states that one of the normal treatment regimens for progressive HCV 
includes a 24- or 48-week course of the combination of pegylated alpha interferon and 
ribavirin(6). 
Alpha interferon is a protein produced by the body with natural antiviral properties.  
Synthetic forms of this protein have been formulated and are used to fight HCV and other 
viral infections. The most common type of interferon used is pegylated or peginterferon. 
Pegylated interferon has a molecule of polyethylene glycol added to the interferon 
molecule that increases the protein’s half –life and stability in the bloodstream.  
Pegylated interferon can thus be injected less frequently than standard interferon. HCV 
also responds at a higher rate to pegylated interferon versus traditional alpha interferon (6). 
 
Ribavirin is an oral antiviral agent that increases the response of the HCV to alpha 
interferon by two to three times.  On its own, ribavirin does not act effectively against the 
HCV and it is not recommended for monotherapy (6).  
The National Institutes of Health Consensus Development Conference Panel has 
recommended that this combination therapy be limited to only “those patients who have 
histological evidence of progressive disease (6).”  Progressive disease is defined as “liver 
fibrosis or moderate to severe inflammation and necrosis determined by a liver biopsy 
(6).”  Patients are not selected based on their individual symptoms, the serum HCV RNA 
levels or genotype, or the mode of HCV acquisition (6).   One exception to this rule is 
applied when the patient has a concurrent Human Immunodeficiency Virus (HIV) 
infection.  The HCV can progress more rapidly in these patients due to the immune 
system breakdown caused by HIV.  As long as there are no contraindications with using 
this combination therapy with the HIV or AIDS medical therapy, interferon can be used 
in the absence of fibrosis or moderate to severe liver necrosis (6).  In 2011, combination 
therapy was also approved for children and adolescents with chronic HCV (11). 
The dosing for combination therapy is dependent on the specific subtype of the patient’s 
HCV.  Genotype 1 of the HCV virus is less responsive to treatment (only 45 to 48 percent 
respond) and thus a full 48- week time course is recommended. The genotypes 2 and 3 
tend to yield a higher response rate of 70 to 80 percent and thus a shorter course of 24 
weeks has been determined to be just as effective as 48- week course of therapy. 
Genotypes 4-6 have not been studied as extensively and therefore follow the longer 
treatment course of genotype 1.  Genotyping of the HCV virus is thus essential to 
determine appropriate time course of treatment and is normally performed before 
combination treatment is initiated (6).   Also note that ribavirin dosing varies with the 
genotyping. 
The combination of pegylated alpha interferon and ribavirin is only determined to be 
successful long- term in the treatment of HCV if the virus’s RNA is undetectable during 
treatment and stays completely undetectable after treatment (determined by serum blood 
testing).   About 70% of patients placed on this regimen have complete disappearance of 
the HCV RNA.  The relapse rate is lower in patients on this combination versus 
monotherapy with just the alpha interferon.   The ultimate goal of this therapy is a 
sustained response, indicated by HCV RNA that remains undetectable for six months or 
more after stopping therapy.  The overall response rate for a 48 -week combination 
therapy is about 55% (6).   
There were no other effective treatments identified if this combination therapy failed until 
December 2013.  The new antiviral, Sofosbuvir, a NS5B polymerase inhibitor was 
approved for addition to pegylated alpha interferon and ribivarin therapy regimen in HCV 
genotypes 1 ,4, 5 and 6.  Then in November 2014, a new antiviral, semeprivir in 
combination with sofosbuvir was approved as a therapy for patients with genotype 1 
monoinfection with HCV. This offers an alternative to patients for whom pegylated alpha 
interferon therapy has not worked.  For genotype 2 or 3 the combination sofosbuvir and 
ribivarin are the very first completely oral therapy for HCV.  The new therapies for HCV 
can be seen in Table 1. 
Table 1: Current Treatments for Hepatitis C 
Genotype 
Category 
Recommend treatment options for 
HCV Mono-infection 
Recommend treatment 
options for HCV /HIV co-
infection 
Genotype 1 • Sofosbuvir + peginterferon-alfa 
+ ribavirin for 12 weeks 
• Interferon ineligible: sofosbuvir 
+ ribavirin for 24 weeks 
• Interferon ineligible: Simeprevir 
• Sofosbuvir + 
peginterferon-alfa 
+ ribavirin for 12 
weeks 
• Interferon 
+ sofosbuvir for 12 (no cirrhosis)  
24 weeks (cirrhosis) 
• In those with hepatocellular 
carcinoma awaiting liver 
transplant: sofosbuvir + ribavirin 
for a duration of up to 48 weeks 




ribavirin for 24 
weeks 
 
Genotype 2 Sofosbuvir + ribavirin for 12 weeks Sofosbuvir + ribavirin for 
12 weeks 
Genotype 3 Sofosbuvir + ribavirin for 24 weeks Sofosbuvir + ribavirin for 
24 weeks 
Genotype 4-6 Not well studied, follow Genotype 1 Not well studied, follow 
Genotype 1 
Though pegylated alpha interferon is useful for treating progressive HCV (and various 
malignancies), ocular side effect from the medication can occur.  Common interferon 
retinopathy ocular signs include cotton wool spots, located especially around the disc, 
retinal hemorrhages and microaneurysms, and white centered hemorrhages (1,2,5,9).  The 
incidence of retinopathy varies in reports from 18-89% of interferon users (2,9).  These 
findings are most often asymptomatic. In more severe cases, branch vein occlusion, 
retinal neovascularization, optic disc edema, pre-retinal or vitreal hemorrhages, retinal 
detachment or cystoid macular edema could occur and lead to severe vision loss (4,5,8).  
Oculomotor paralysis has also been reported (8).  Interferon retinopathy can occur anytime 
during the course of therapy, though most commonly begins within the first month of 
treatment (9). Retinopathy can also occur just after stopping therapy (9).  Fluorescein 
angiography can further reveal signs of interferon retinopathy.  Retinal hemorrhages are 
seen as a blocking of background fluorescence.  Non-perfused areas in the retina will 
indicate the cotton wool spots.  Table 2 lists the common retinal findings reported in 
interferon HCV therapy. 
Table 2: Interferon- Related Ocular Complications Reported (4,5,8) 




Branch vein occlusion 
Retinal neovascularization 
Neovascular glaucoma 
Optic disc edema 
Pre-retinal or vitreal hemorrhages  
Retinal Detachment 
Cystoid macular edema  
Oculomotor paralysis 
 
The pathogenesis of interferon retinopathy is still largely undetermined.  Microcirculation 
injuries leading to ischemia has been determined to be the most likely cause by studies 
using fluorescein angiography. These studies demonstrate poor retinal perfusion in eyes 
with interferon retinopathy (2,4,5).   Another proposed mechanism is damage caused by 
immune complex deposition. About 10% of patients will develop antibodies to alpha 
interferon (2,8,9). Leukocyte infiltration of vascular endothelium has also been postulated 
to lead to vascular damage in various animal models (3,8). 
A side effect of treatment with interferon is the development of systemic anemia.  
Anemia-induced tissue hypoxia may result from a decrease in the amount of oxygen 
delivered to retinal tissues.  In a study of retinal blood flow measured by Doppler 
imaging, it was postulated that an increase in retinal blood flow might result from a drop 
in oxygen secondary to anemia. The retinal blood flow rate would increase to compensate 
for low oxygen content (4,8).    
Risk factors for developing interferon retinopathy have been identified. Studies have 
correlated not only higher dosages of interferon (5), but also the use of the specific type, 
pegylated interferon (2) to increased risk of interferon retinopathy.  Intravenous or 
intramuscular injection treatments of interferon range from 3x106 units three times a 
week to 9x106 units six times a week (2,7,9). This dosage is usually tapered over time and 
can vary to treat different HCV types. In addition to the use of interferon, systemic 
hypertension, diabetes mellitus, and increased triglycerides are also risk factors as they 
can lead to microvascular insult even independently of interferon therapy (2,8).  Increased 
age was also identified as a possible risk factor. The one thing that has not been identified 
as a risk factor in the literature is the use of ribivarin with pegylated interferon.  Risk 
factors for the development of interferon retinopathy can be seen in Table 3. 
 
Table 3: Risk Factor for the Development of Interferon Retinopathy 
Increased dosage level of interferon 







Interferon retinopathy shares many similar findings with other vascular diseases in the 
eye.  Diabetic retinopathy, hypertensive retinopathy, and vascular occlusions can all 
include cotton wool spots and retinal hemorrhages (2,8).   Early HIV retinopathy is also 
hallmarked by isolated cotton wool spots. As mentioned before, any of these conditions 
when concurrent with HCV interferon treatment can increase the risk of interferon 
retinopathy
 (2,8).  It is therefore, crucial to run blood and serology laboratory medical tests 
to rule in or out these conditions.   If interferon therapy is discontinued, the signs of 
retinopathy will generally dissipate within 4-6 weeks, which in itself can make the 
diagnosis definitive. 
Pegylated Alpha Interferon therapy can also cause systemic side effects including: 
fatigue, muscle aches, headaches, nausea and vomiting, skin irritation at the injection site, 
low-grade fever, weight loss, irritability, depression, mild bone marrow suppression, and 
reversible hair loss.  Ribavirin, used in the combination therapy also causes side effects 
including:  anemia, fatigue, irritability, itching skin rash, nasal congestiom, sinusitis, and 
cough (6).  The combination therapy does tend to cause more side effects versus alpha 
interferon monotherapy.  Other less common side effects include: autoimmune disease 
(especially thyroid disease), severe bacterial infections, marked thrombocytopenia and 
neutropenia, seizures, depression and suicidal ideation or attempts, hearing loss and 
tinnitus (6).   Even in the face of all the possible side effects patients with severe end stage 
liver disease often choose to take the risks of treatment in order postpone the need for 
liver transplantation. 
Conclusions 
Patients who are placed on interferon therapy should have a baseline complete eye 
examination including careful evaluation of the fundus. This will help to rule out any pre-
existing retinopathy, especially in those who have concurrent vascular health problem.  
The patient should be monitored during the course of the projected treatment, at three (9) 
month intervals in those with no pre-existing retinopathy and monthly in those with 
retinopathy before treatment. The patient should also be educated to return for an 
examination immediately if any changes in vision are noted. 
The decision to stop interferon therapy secondary to findings of retinopathy must be 
weighed carefully. Most often the benefits of the therapy systemically will outweigh the 
risk of visual impairment. In this case, the patient elected to protect his liver health and 
continue his interferon therapy, as there were no signs of visual impairment other than a 
mildly bothersome visual field disturbance.  Monitoring the eye health alone seemed to 
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